Primary acute dengue and the deletion in chemokine receptor 5 (CCR5δ32)

Microbes and Infection

Volumn 16, Issue 6, 2014, Pages 518-521

  Brestovac, Brian ^a   Halicki, Larissa A ^a   Harris, Ryan P ^a   Sampson, Ian ^b   Speers, David J ^b,c   Mamotte, Cyril ^a   Williams, David ^a,b  

^a CURTIN UNIVERSITY   (Australia)

^b PATHWEST LABORATORY MEDICINE   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cysteine cysteine chemokine receptor 5 (CCR5); Cysteine cysteine chemokine receptor 5 32 base deletion (CCR5 32); Dengue virus (DENV); Flavivirus; Vector

Indexed keywords

CHEMOKINE RECEPTOR CCR5;

ACUTE DISEASE; AEDES AEGYPTI; AEDES ALBOPICTUS; ARTICLE; AUSTRALIA; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DISEASE CARRIER; GENE DELETION; GENE FREQUENCY; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; SOUTHERN EUROPE; TRAVEL; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; MUTATION;

DENGUE VIRUS; FLAVIVIRUS;

ACUTE DISEASE; CASE-CONTROL STUDIES; DENGUE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; RECEPTORS, CCR5; SEQUENCE DELETION; WESTERN AUSTRALIA;

EID: 84902774597     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2014.02.007     Document Type: Article

References (25)

1. Halstead S.B. Dengue. Lancet 2007, 370:1644-1652.
2. McConnell J. 15th international congress on infectious diseases. Lancet Infect Dis 2012, 12:593.
3. Loeb M. Genetic susceptibility to West Nile virus and dengue. Public Health Genomics 2013, 16:4-8.
4. Whitehorn J., Simmons C.P. The pathogenesis of dengue. Vaccine 2011, 29:7221-7228.
5. Rigau-Pérez J.G. Severe dengue: the need for new case definitions. Lancet Infect Dis 2006, 6:297-302.
6. Coffey L.L., Mertens E., Brehin A.C., Fernandez-Garcia M.D., Amara A., Després P., et al. Human genetic determinants of dengue virus susceptibility. Microbes Infect 2009, 11:143-156.
7. Chaturvedi U.C., Nagar R., Shrivastava R. Dengue and dengue haemorrhagic fever: implications of host genetics. FEMS Immunol Med Microbiol 2006, 47:155-166.
8. Warrilow D., Northill J.A., Pyke A.T. Sources of dengue viruses imported into Queensland, Australia, 2002-2010. Emerg Infect Dis 2012, 18:1850-1857.
9. Medlock J.M., Hansford K.M., Schaffner F., Versteirt V., Hendrickx G., Zeller H., et al. A review of the invasive mosquitoes in Europe: ecology, public health risks, and control options. Vector Borne Zoonotic Dis 2012, 12:435-447.
10. Semenza J.C., Menne B. Climate change and infectious diseases in Europe. Lancet Infect Dis 2009, 9:365-375.
11. Semenza J.C., Apfel F., Rose T., Giesecke J. A network strategy to advance public health in Europe. Eur J Public Health 2008, 18:441-447.
12. Laing K.J., Secombes C.J. Chemokines. Dev Comp Immunol 2004, 28:443-460.
13. Klitz W., Brautbar C., Schito A.M., Barcellos L.F., Oksenberg J.R. Evolution of the ccr5 delta32 mutation based on haplotype variation in Jewish and northern European population samples. Hum Immunol 2001, 62:530-538.
14. Lucotte G. Distribution of the ccr5 gene 32-basepair deletion in west Europe. A hypothesis about the possible dispersion of the mutation by the Vikings in historical times. Hum Immunol 2001, 62:933-936.
15. D'Souza M.P., Harden V.A. Chemokines and hiv-1 second receptors. Confluence of two fields generates optimism in aids research. Nat Med 1996, 2:1293-1300.
16. Dean M., Carrington M., Winkler C., Huttley G.A., Smith M.W., Allikmets R., et al. Genetic restriction of hiv-1 infection and progression to aids by a deletion allele of the ckr5 structural gene. Science 1996, 273:1856-1862.
17. Glass W.G., McDermott D.H., Lim J.K., Lekhong S., Yu S.F., Frank W.A., et al. Ccr5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006, 203:35-40.
18. Lim J.K., McDermott D.H., Lisco A., Foster G.A., Krysztof D., Follmann D., et al. Ccr5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. J Infect Dis 2010, 201:178-185.
19. Glass W.G., Lim J.K., Cholera R., Pletnev A.G., Gao J.L., Murphy P.M. Chemokine receptor ccr5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med 2005, 202:1087-1098.
20. Kindberg E., Mickiene A., Ax C., Akerlind B., Vene S., Lindquist L., et al. A deletion in the chemokine receptor 5 (ccr5) gene is associated with tickborne encephalitis. J Infect Dis 2008, 197:266-269.
21. Pulendran B., Miller J., Querec T.D., Akondy R., Moseley N., Laur O., et al. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in ccr5 and rantes genes. J Infect Dis 2008, 198:500-507.
22. Larena M., Regner M., Lobigs M. The chemokine receptor ccr5, a therapeutic target for HIV/AIDS antagonists, is critical for recovery in a mouse model of Japanese encephalitis. PLoS ONE 2012, 7:e44834.
23. Sierra B., Perez A.B., Garcia G., Aguirre E., Alvarez M., Gonzalez D., et al. Role of cc chemokine receptor 1 and two of its ligands in human dengue infection. Three approaches under the Cuban situation. Microbes Infect 2014, 16:40-50.
24. Abdi R., Tran T.B.H., Sahagun-Ruiz A., Murphy P.M., Brenner B.M., Milford E.L., et al. Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol 2002, 13:754-758.
25. Li L., Sun T., Yang K., Zhang P., Jia W.Q. Monoclonal ccr5 antibody for treatment of people with HIV infection. Cochrane Database Syst Rev 2010, CD008439.